The results revealed that CMTM6 was upregulated in six [breast invasive carcinoma (BLCA), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), kidney renal papillary cell carcinoma (KIRP), stomach adenocarcinoma (STAD), and thyroid carcinoma (THCA)] and downregulated in six [cholangiocarcinoma (CHOL), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and pheochromocytoma and paraganglioma (PCPG)] cancer types relative to that in normal tissues (Figure 1A). Here, CMTM6 is linked to pheochromocytoma-paraganglioma.